Free Trial

Artemis Investment Management LLP Has $48.03 Million Stock Position in Avantor, Inc. (NYSE:AVTR)

Avantor logo with Medical background

Artemis Investment Management LLP trimmed its position in Avantor, Inc. (NYSE:AVTR - Free Report) by 23.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,963,239 shares of the company's stock after selling 918,848 shares during the period. Artemis Investment Management LLP owned approximately 0.43% of Avantor worth $48,034,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Dodge & Cox raised its holdings in Avantor by 44.9% in the fourth quarter. Dodge & Cox now owns 99,145,770 shares of the company's stock worth $2,089,001,000 after purchasing an additional 30,727,673 shares during the period. Barrow Hanley Mewhinney & Strauss LLC lifted its holdings in Avantor by 41.4% during the fourth quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 30,528,092 shares of the company's stock worth $643,227,000 after acquiring an additional 8,936,879 shares in the last quarter. Norges Bank acquired a new position in Avantor in the fourth quarter valued at about $142,512,000. The Manufacturers Life Insurance Company increased its holdings in shares of Avantor by 48.3% in the fourth quarter. The Manufacturers Life Insurance Company now owns 9,158,175 shares of the company's stock worth $192,963,000 after acquiring an additional 2,983,439 shares in the last quarter. Finally, Clarkston Capital Partners LLC raised its position in shares of Avantor by 43.6% during the fourth quarter. Clarkston Capital Partners LLC now owns 8,145,825 shares of the company's stock worth $171,633,000 after purchasing an additional 2,473,395 shares during the period. Institutional investors own 95.08% of the company's stock.

Insider Activity

In other Avantor news, Director Joseph R. Massaro acquired 8,100 shares of the company's stock in a transaction on Tuesday, April 29th. The shares were purchased at an average price of $12.30 per share, for a total transaction of $99,630.00. Following the completion of the purchase, the director now directly owns 35,038 shares of the company's stock, valued at approximately $430,967.40. This represents a 30.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gregory L. Summe bought 30,000 shares of Avantor stock in a transaction dated Friday, May 23rd. The shares were acquired at an average price of $12.50 per share, with a total value of $375,000.00. Following the completion of the purchase, the director now directly owns 100,000 shares in the company, valued at $1,250,000. This trade represents a 42.86% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders purchased 83,100 shares of company stock valued at $1,027,630. 1.20% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts recently issued reports on AVTR shares. Barclays decreased their price objective on Avantor from $18.00 to $15.00 and set an "overweight" rating for the company in a research report on Monday, April 28th. The Goldman Sachs Group cut shares of Avantor from a "buy" rating to a "neutral" rating and reduced their price target for the company from $23.00 to $14.00 in a report on Tuesday, April 29th. TD Cowen downgraded shares of Avantor from a "buy" rating to a "hold" rating and set a $15.50 price objective for the company. in a research report on Monday, April 28th. Morgan Stanley cut shares of Avantor from an "overweight" rating to an "equal weight" rating in a research report on Tuesday, April 29th. Finally, Cowen lowered shares of Avantor from a "buy" rating to a "hold" rating in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Avantor currently has an average rating of "Hold" and a consensus target price of $18.88.

Check Out Our Latest Stock Analysis on AVTR

Avantor Stock Down 0.4%

Shares of NYSE AVTR traded down $0.05 during mid-day trading on Monday, hitting $13.48. The company had a trading volume of 4,259,572 shares, compared to its average volume of 8,337,126. The company has a current ratio of 1.12, a quick ratio of 0.75 and a debt-to-equity ratio of 0.54. The firm has a 50-day simple moving average of $13.23 and a two-hundred day simple moving average of $16.82. The company has a market capitalization of $9.19 billion, a PE ratio of 12.96, a price-to-earnings-growth ratio of 1.44 and a beta of 1.04. Avantor, Inc. has a one year low of $11.82 and a one year high of $28.00.

Avantor (NYSE:AVTR - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $0.23 earnings per share for the quarter, meeting analysts' consensus estimates of $0.23. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a return on equity of 11.93% and a net margin of 10.70%. The business's revenue was down 5.9% compared to the same quarter last year. During the same period last year, the company earned $0.22 earnings per share. On average, equities analysts expect that Avantor, Inc. will post 1.06 EPS for the current year.

Avantor Profile

(Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Recommended Stories

Institutional Ownership by Quarter for Avantor (NYSE:AVTR)

Should You Invest $1,000 in Avantor Right Now?

Before you consider Avantor, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.

While Avantor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

This Strategy Beat the S&P—And Most Investors Ignore It
Time to Cash Out? 5 Stocks to Drop Before Earnings
Watch Before Monday: Stocks to Load Up on Before Earnings

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines